James L. Riley

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

This study modifies NK cells to express CD64 and pre-load them with HIV-specific BNAbs, enhancing their ability to target HIV-infected CD4+ T cells via ADCC.

This study shows that overexpressing Rab5 prevents CAR internalization by tumors, maintains CAR surface expression, and improves CART efficacy against solid tumors.

This paper discovers and engineers an HIV-1 Therapeutic Interfering Particle (TIP) that suppresses viral replication and protects CD4+ T cells in humanized mice.